Fidelity Disruptive Medicine Fund (FMEDX)
Fidelity Disruptive Medicine Fund operates in the Asset Management industry of the Financial Services sector, headquartered in Boston, MA, US. The stock last traded at $11.28, down 0.18% on the session, giving a market capitalisation of $43.2M. Its beta of 0.78 implies it has historically moved less than the broad market.
The fund primarily directs at least 80% of its total assets into companies that are leading advancements in the medical sector. Its core investments largely consist of equity instruments. According to the Adviser, "disruptive medicine" companies encompass, but are not limited to, those engaged in fields such as robotic surgical procedures, gene therapy, genomic research, treatments for rare conditions, cutting-edge medical devices and apparatus, immunotherapy, digital healthcare platforms, and initiatives promoting consumer well-being. It is important to note that this fund operates as a non-diversified portfolio.
Fidelity Disruptive Medicine Fund is most often compared with the following Financial Services names: